Next-generation TKIs (osimertinib) or intercalated therapy may be considered in patients with EGFR T790M variants or those more likely to develop tumor progression.9,10,11 Recent clinical studies12,13,14 have suggested that the efficacy of EGFR-TKIs should be evaluated before clinical decision-making and alternative treatments potentially prioritized in patients at high risk for rapid tumor progression. This evidence concerns the gene EGFR and neoplasm.